

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Abattis Bioceuticals Corp.
Suite 1040 – 885 West Georgia Street
Vancouver, BC V6C 3E8

Item 2. Date of Material Change

May 11, 2015

Item 3. News Release

A news release dated and disseminated May 11, 2015 at Vancouver, British Columbia, through The Newswire.ca, CSE Markets and SEDAR is attached as Schedule "A".

Item 4. Summary of Material Change

See news release, a copy of which is attached hereto.

Item 5. Full Description of Material Change

See news release, a copy of which is attached hereto.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Rene David, CFO & COO
Telephone: 604.336.0881

Item 9. Date of Report

May 21, 2015



Rene David

Schedule "A"

Suite 1040 – 885 West Georgia St.
Vancouver, BC V6C 3E8
Tel: (604) 336.0881
Email: news@abattis.com



Abattis selects Ingredient Identity as Global Regulatory Management Partner

Vancouver, BC - May 11, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, is pleased to announce the engagement of Ingredient Identity, a preeminent regulatory management consulting firm to the Food, Dietary Supplement, Cosmetic and Homeopathic industries globally.

After a rigorous qualification effort to find the right regulatory consultancy to support Abattis' operations and global product development strategy, the selection of Ingredient Identity was made due to their legacy of quality and regulatory expertise throughout domestic and international markets, their highly customizable project management capabilities and the seamless scalability of their service offerings.

"Ingredient Identity has a profound team, knowledge-base and portfolio of services to support our growth in various target markets. Such will enable us as a whole to achieve and maintain an optimal balance between meeting our core growth objectives, and ensuring our commitment to quality and regulatory compliance," said Dr. Brazos Minshew, Chief Science Officer of Abattis.

"Abattis' and its subsidiary companies presented us with one of the most fun and unique opportunities to date in the history of our firm. We created an incredibly comprehensive solution to work closely with the Abattis team now and seamlessly as it grows. Our work will help define, optimize and maintain not only their product development strategy, but also their quality and compliance requirements across different business entities and divisions thereof, including outside contract vendors throughout various regulatory landscapes," said Brandon Griffin, CEO of Ingredient Identity.

Abattis, through its subsidiary companies, will leverage Ingredient Identity for ingredient and formulation reviews, label reviews and claims substantiations, specification writing and other general FTC/FDA compliance matters in a highly proactive manner. General support will include developing and maintaining standard operating procedures, vendor GMP facility auditing, establishing Quality Agreements and providing internal teams with dedicated outsourced QA/QC resources. Ingredient Identity will also be engaged by Abattis' executive management to help guide strategic planning efforts for product development and market penetration initiatives that better ensure streamlined and cost-efficient growth while mitigating overall legal and regulatory liabilities.

About Ingredient Identity

Ingredient Identity is a preeminent regulatory management consultancy supporting companies in the Food, Dietary Supplement, Cosmetic and Homeopathic industries worldwide. The company specializes in quality and regulatory guidance strategies, FDA compliance, risk mitigation, quality system optimization and New Dietary Ingredient Notifications and GRAS dossier submissions. For more information: www.ingredientidentity.com

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, and patented equipment to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also

has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Bill Fleming"

Bill Fleming, CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.